iBioLaunch to be used to develop anthrax and plague vaccine

iBio, Inc., a biopharmaceutical company, has confirmed that its has granted rights for its iBioLaunch propietary technology to be used in support of a government-funded project developing a single vaccine to protect against both anthrax and plague.

Fraunhofer USA Center for Molecular Biotechnology will manage the project pursuant to a long-term agreement between iBio and Fraunhofer USA Center for Molecular Biotechnology for advancement of the iBio technology.

"We are confident in our ability to deliver on the objective of this contract," Dr. Vidadi Yusibov, executive director of Fraunhofer USA Center for Molecular Biotechnology, said. "We expect to demonstrate the safety and efficacy of a one-shot vaccine in animal tests in preparation for clinical development."

iBio and Fraunhofer USA Center for Molecular Biotechnology have developed a new biologics production platform that is based upon the use of green plants to manufacture vaccines and therapeutic proteins. To date, the technology has successfully been applied to a variety of candidate products, include avian influenza vaccine that will its first product to enter a human clinical trial in 2010.

"We believe this program will further demonstrate the ability of our technology to produce novel products rapidly, effectively and economically," Robert Kay, chairman and chief executive officer of iBio, Inc., said.